Home › Nasopharyngeal Carcinoma › Georgia
Nasopharyngeal Carcinoma clinical trials in Georgia
6 studies for Nasopharyngeal Carcinoma are looking for participants at sites in Georgia.
Cities in Georgia
Testing Whether Cemiplimab (REGN2810) Plus CDX-1140 Given Prior to Surgery Are Better Than Cemiplimab (REGN2810) Alone in Patients With Stage III-IV Head and Neck Cancer
- Emory University Hospital Midtown, Atlanta
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT06980038Testing the Addition of BMS-986016 (Relatlimab) to the Usual Immunotherapy After Initial Treatment for Recurrent or Metastatic Nasopharyngeal Cancer
- Emory University Hospital Midtown, Atlanta
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 16, 2026 · NCT06029270A Study Using Nivolumab, in Combination With Chemotherapy Drugs to Treat Nasopharyngeal Carcinoma (NPC)
- Children's Healthcare of Atlanta - Arthur M Blank Hospital, Atlanta
RecruitingPhase 2
Up to age 21 · All sexes · Updated Sep 14, 2026 · NCT06064097Remote Audiometry to Monitor for Treatment-Related Hearing Loss in Patients With H&N SCC Receiving Cisplatin and/or Radiation
- Emory Midtown University Hospital/Winship Cancer Institute, Atlanta
Recruiting
Ages 18 and older · All sexes · Updated Jul 16, 2026 · NCT06662058TMV Vaccine Therapy Alone and With Pembrolizumab for the Treatment of Recurrent and/or Metastatic Head and Neck Squamous Cell Cancer
- Emory University Hospital Midtown, Atlanta
- Emory University Hospital/Winship Cancer Institute, Atlanta
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Mar 4, 2026 · NCT06868433Lovastatin and Pembrolizumab for the Treatment of Patients With Recurrent or Metastatic Head and Neck Cancer, LAPP Trial
- Emory University Hospital Midtown, Atlanta
- Emory University Hospital/Winship Cancer Institute, Atlanta
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Feb 11, 2026 · NCT06636734From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.